US EditionBiden wanted Medicaid to pay for weight-loss drugs. Trump just said it doesn’t have to
- The Trump administration recently rescinded a Biden-era rule requiring Medicaid to cover high-cost GLP-1 weight-loss drugs, allowing states to decide coverage individually.
- This change followed concerns from state Medicaid directors over financial impacts and objections to mandatory coverage despite evidence of health and economic benefits.
- Aon analyzed health claims from a dataset encompassing over 50 million individuals with commercial insurance, finding that GLP-1 medications contribute to slower healthcare cost growth and significantly reduce the risk of major cardiovascular events.
- CEO Greg Case emphasized that combining GLP-1 drugs with a comprehensive adherence strategy offers a unique chance to effectively address and control chronic illnesses, potentially leading to significant cost reductions.
- The rollback of Medicaid’s coverage mandate leaves drug access uneven across states, suggesting long-term workforce health and economic outcomes may vary according to state policy choices.
19 Articles
19 Articles
New Hampshire Union Leader
The DerrickBiden wanted Medicaid to pay for weight-loss drugs. Trump just said it doesn’t have to
The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, state Medicaid programs will retain the choice of whether to cover…
Aon Unveils First Workforce-Focused Analysis on GLP-1s: Medications and Holistic Support Can Transform Workforce Health and Bend the Cost Curve
Firm also sets new standard in employee health by combining GLP-1 medications and holistic support to drive adherence and sustainable outcomes for Aon's U.S. colleagues in collaboration with eMed
Biden wanted Medicaid to pay for weight-loss drugs. Trump said it doesn’t have to
The Biden administration proposed a rule that would have required state Medicaid programs to cover GLP-1s for obesity treatment, but the Trump administration said it will leave the option up to the states (Scott Olson/Getty Images).The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, state Medicaid pro…
Biden wanted Medicaid to pay for weight-loss drugs. Trump just said it doesn’t have to.
The Biden administration proposed a rule that would have required state Medicaid programs to cover GLP-1 medications like Wegovy for obesity treatment, but the Trump administration said it will leave the option up to the states. (Scott Olson/Getty Images)The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Inst…
Coverage Details
Bias Distribution
- 71% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
